- Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives
-
Hirmas N, Jadaan R, Al-Ibraheem A
- KMID: 2414809
- Nucl Med Mol Imaging.
- 2018 Jun;52(3):190-199.
- doi: 10.1007/s13139-018-0517-x
PURPOSE AND METHODS: Patients with inoperable andmetastasized neuroendocrine tumors (NETs), particularly those with grades 1 and 2, usually receive treatment with somatostatin analogues (SSAs). Peptide receptor radionuclide therapy (PRRT) has... -
- CITED
-
- Close
- SHARE
-
- Close
- Development of a Small Animal Positron Emission Tomography Using Dual-Layer Phoswich Detector and Position Sensitive Photomultiplier Tube: Preliminary Results
-
Jeong MH, Choi Y, Chung YH, Song TY, Jung JH, Hong KJ, Min BJ, Choe YS, Lee KH, Kim BT
- KMID: 1516859
- Korean J Nucl Med.
- 2004 Oct;38(5):338-343.
PURPOSE: The purpose of this study was to develop a small animal PET using dual layer phoswich detector to minimize parallax error that degrades spatial resolution at the outer part... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Status and Growth of Nuclear Theranostics in Singapore
-
Huang HL, Tong AK, Thang SP, Yan SX, Lam WW, Loke KS, Tang CY, Cheng LT, Ooi GS, Low HC, Magsombol , Tham WY, Goh CX, Tan CJ, Khor YM, Zaheer S, Bharadwaj , Xie W, Ng DC
- KMID: 2448096
- Nucl Med Mol Imaging.
- 2019 Apr;53(2):96-101.
- doi: 10.1007/s13139-019-00580-3
The concept of theranostics, where individual patient-level biological information is used to choose the optimal therapy for that individual, has become more popular in the modern era of ‘personalised’ medicine.... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status
-
Gupta M, Choudhury , Rawal S, Karthikeyan G, Talwar V, Dutta KD, Singh A
- KMID: 2469586
- Nucl Med Mol Imaging.
- 2019 Dec;53(6):423-431.
- doi: 10.1007/s13139-019-00624-8
PURPOSE: The aim of this study was to evaluate safety and therapeutic efficacy of lutetium 177 prostate-specific membrane antigen (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with low performance... -
- CITED
-
- Close
- SHARE
-
- Close
